文献速递妇科产科

BRCA1/2致病性变异携带者中避孕措施与癌症风险:系统综述与荟萃分析

Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis.
PubMed 文献 · Hum Reprod Update · 2023-01-01

该系统综述与荟萃分析旨在优化BRCA1/2致病性变异携带者的避孕咨询,检索Medline和Cochrane图书馆至2021年6月,分析使用任何避孕措施者与非使用者的乳腺癌和卵巢癌风险比,并概述相关国际指南。口服避孕药可能增加乳腺癌风险(HR 1.55,95%CI 1.36-1.76),但降低卵巢癌风险(HR 0.62,95%CI 0.52-0.74);输卵管结扎也降低卵巢癌风险。证据质量低或极低。

要点

  • 口服避孕药使用者的乳腺癌风险HR为1.55(95%CI 1.36-1.76),证据质量低或极低。
  • 口服避孕药使用者的卵巢癌风险HR为0.62(95%CI 0.52-0.74),但保护效应在停药后消失。
  • 输卵管结扎与卵巢癌风险降低相关(HR 0.44,95%CI 0.26-0.74),证据质量低或极低。

核心结论

  • 口服避孕药可能增加BRCA1/2-PV携带者的乳腺癌风险,同时口服避孕药和输卵管结扎降低卵巢癌风险。
  • 对BRCA1/2-PV携带者的咨询应个体化,平衡遗传和非遗传因素及患者偏好。

研究设计与样本

  • 系统综述与荟萃分析,检索Medline和Cochrane图书馆至2021年6月,遵循PRISMA指南,进行ROBINS-I和GRADE评估,采用随机效应荟萃分析。

主要发现

  • 口服避孕药与乳腺癌风险:7项研究7525名女性,HR 1.55(95%CI 1.36-1.76),异质性I²=0%;4项研究9106名女性,OR 1.06(95%CI 0.90-1.25),异质性I²=52%。
  • 末次口服避孕药使用超过10年后,曾使用者乳腺癌风险仍高于从未使用者。
  • 口服避孕药与卵巢癌风险:2项研究10981名女性,HR 0.62(95%CI 0.52-0.74),异质性I²=0%;8项研究10390名女性,OR 0.49(95%CI 0.38-0.63),异质性I²=64%;保护效应在停药后消失。
  • 输卵管结扎与卵巢癌风险:1项研究3319名女性,HR 0.44(95%CI 0.26-0.74),异质性I²=0%;3项研究7691名女性,OR 0.74(95%CI 0.53-1.03),异质性I²=44%。
  • BRCA1与BRCA2-PV携带者之间未观察到差异;其他避孕措施的数据不可用;证据质量低或极低。

关键数值与推荐

  • 口服避孕药与乳腺癌风险的HR为1.55(95%CI 1.36-1.76),基于7项研究7525名女性,异质性I²=0%。
  • 口服避孕药与卵巢癌风险的HR为0.62(95%CI 0.52-0.74),基于2项研究10981名女性,异质性I²=0%。
  • 输卵管结扎与卵巢癌风险的HR为0.44(95%CI 0.26-0.74),基于1项研究3319名女性,异质性I²=0%。

临床怎么用

  • 对BRCA1/2-PV携带者的避孕咨询应个体化,平衡遗传和非遗传因素(如既往降低风险手术、既往乳腺癌和年龄)及患者偏好(可逆性、易用性、可靠性和对月经周期的影响)。
  • 未来研究应关注其他常用避孕措施及该人群的癌症风险,以及避孕配方随时间变化的潜在影响。

局限性

  • 证据质量低或极低。
  • 其他避孕措施的数据不可用。
  • 未来研究应关注其他常用避孕措施和癌症风险,以及避孕配方随时间变化的潜在影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increasing numbers of BReast CAncer (BRCA) 1 or 2 pathogenic variant (PV) carriers, who have an inherited predisposition to breast and ovarian cancer, are being identified. Among these women, data regarding the effects of contraception on cancer risks are unclear and various guidelines provide various recommendations. OBJECTIVE AND RATIONALE: We aim to optimize counselling regarding contraception for BRCA1/2-PV carriers. Therefore, we performed a systematic review and meta-analysis. We investigated the risk ratio for developing breast cancer or ovarian cancer in BRCA1/2-PV carriers who have used any form of contraception versus non-users. Second, we analysed breast and ovarian cancer risk among BRCA1/2-PV carriers as influenced by the duration of contraceptive use and by the time since last use. In addition, we provide an overview of all relevant international guidelines regarding contraceptive use for BRCA1/2-PV carriers. SEARCH METHODS: A systematic search in the Medline database and Cochrane library identified studies describing breast and/or ovarian cancer risk in BRCA1/2-PV carriers as modified by contraception until June 2021. The search included medical subject headings, keywords and synonyms related to BRCA and contraceptives (any kind). PRISMA guidance was followed. Risk Of Bias In Non-randomized Studies of Interventions and Grading of Recommendations, Assessment, Development and Evaluations assessments were performed. Random-effects meta-analyses were used to estimate pooled effects for breast and ovarian cancer risk separately. Subgroup analyses were conducted for BRCA1 versus BRCA2 and for the various contraceptive methods. OUTCOMES: Results of the breast cancer risk with oral contraceptive pill (OCP) analysis depended on the outcome measure. Meta-analyses of seven studies with 7525 women revealed a hazard ratio (HR) of 1.55 (95% CI: 1.36-1.76) and of four studies including 9106 women resulted in an odds ratio (OR) of 1.06 (95% CI: 0.90-1.25), heterogeneity (I2) 0% and 52%, respectively. Breast cancer risk was still increased in ever-users compared with never-users >10 years after last OCP use. In contrast, ovarian cancer risk was decreased among OCP users: HR 0.62 (95% CI: 0.52-0.74) based on two studies including 10 981 women (I2: 0%), and OR 0.49 (95% CI: 0.38-0.63) based on eight studies including 10 390 women (I2: 64%). The protective effect vanished after cessation of use. Tubal ligation also protects against ovarian cancer: one study including 3319 women (I2: 0%): HR: 0.44 (95% CI: 0.26-0.74) and three studies with 7691 women (I2: 44%): OR: 0.74 (95% CI: 0.53-1.03). Data regarding other contraceptives were unavailable. No differences were observed between BRCA1 and BRCA2-PV carriers. The quality of evidence was either low or very low. WIDER IMPLICATIONS: The OCP potentially increases breast cancer risk, while ovarian cancer risk decreases with either the OCP and tubal ligation in BRCA1/2-PV carriers. Counselling of BRCA1/2-PV carriers should be personalized; the genetic and non-genetic factors (like prior risk-reducing surgeries, prior breast cancer and age) and patients' preferences (reversibility, ease of use, reliability and effect on menstrual cycle) should be balanced. To further optimize counselling for high-risk women, future research should focus on other (commonly used) contraceptive methods and cancer risks in this specific population, and on the potential impact of changing formulations over time.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. van Bommel MHD, IntHout J, Veldmate G, et al. Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis. Hum Reprod Update. 2023. PMID: 36383189. doi:10.1093/humupd/dmac038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。